Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer

The company revealed Thursday that its PD-1 fighter, against placebo, had lengthened the time muscle-invasive urothelial carcinoma patients could remain disease-free after surgery. All patients saw benefit, regardless of whether their tumors expressed levels of biomarker PD-L1.